Syngene International Past Earnings Performance
Past criteria checks 2/6
Syngene International has been growing earnings at an average annual rate of 6.2%, while the Life Sciences industry saw earnings growing at 25.2% annually. Revenues have been growing at an average rate of 14.2% per year. Syngene International's return on equity is 11%, and it has net margins of 14%.
Key information
6.2%
Earnings growth rate
5.9%
EPS growth rate
| Life Sciences Industry Growth | 11.2% |
| Revenue growth rate | 14.2% |
| Return on equity | 11.0% |
| Net Margin | 14.0% |
| Last Earnings Update | 30 Sep 2024 |
Recent past performance updates
Recent updates
Revenue & Expenses Breakdown
How Syngene International makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
| Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
|---|---|---|---|---|
| 30 Sep 24 | 34,511 | 4,819 | 9,808 | 0 |
| 30 Jun 24 | 34,702 | 4,923 | 9,548 | 0 |
| 31 Mar 24 | 34,886 | 5,100 | 9,403 | 0 |
| 31 Dec 23 | 35,661 | 5,002 | 9,516 | 0 |
| 30 Sep 23 | 34,985 | 4,984 | 9,415 | 0 |
| 30 Jun 23 | 33,565 | 4,839 | 9,232 | 0 |
| 31 Mar 23 | 31,929 | 4,644 | 8,939 | 0 |
| 31 Dec 22 | 29,566 | 4,334 | 8,100 | 0 |
| 30 Sep 22 | 28,121 | 4,277 | 7,880 | 0 |
| 30 Jun 22 | 26,542 | 3,924 | 7,654 | 0 |
| 31 Mar 22 | 26,042 | 3,958 | 7,504 | 0 |
| 31 Dec 21 | 25,047 | 4,086 | 7,461 | 0 |
| 30 Sep 21 | 24,478 | 4,068 | 7,333 | 0 |
| 30 Jun 21 | 23,572 | 4,242 | 7,099 | 0 |
| 31 Mar 21 | 21,843 | 4,049 | 6,792 | 0 |
| 31 Dec 20 | 21,330 | 3,645 | 6,619 | 0 |
| 30 Sep 20 | 20,676 | 3,541 | 6,382 | 0 |
| 30 Jun 20 | 20,126 | 3,981 | 6,088 | 0 |
| 31 Mar 20 | 20,119 | 4,121 | 6,006 | 0 |
| 31 Dec 19 | 19,385 | 3,920 | 5,780 | 0 |
| 30 Sep 19 | 18,865 | 3,872 | 5,446 | 0 |
| 30 Jun 19 | 18,405 | 3,374 | 5,277 | 0 |
| 31 Mar 19 | 18,256 | 3,316 | 5,032 | 0 |
| 31 Dec 18 | 17,008 | 3,160 | 4,733 | 0 |
| 30 Sep 18 | 16,214 | 3,110 | 4,502 | 0 |
| 30 Jun 18 | 15,380 | 3,096 | 4,290 | 0 |
| 31 Mar 18 | 14,231 | 3,054 | 4,073 | 0 |
| 31 Dec 17 | 13,053 | 2,993 | 3,722 | 0 |
| 30 Sep 17 | 12,497 | 2,917 | 3,565 | 0 |
| 30 Jun 17 | 12,175 | 2,895 | 3,395 | 0 |
| 31 Mar 17 | 12,009 | 2,873 | 3,274 | 0 |
| 31 Dec 16 | 12,411 | 2,682 | 3,220 | 0 |
| 30 Sep 16 | 11,894 | 2,606 | 3,021 | 0 |
| 30 Jun 16 | 11,479 | 2,344 | 2,826 | 0 |
| 31 Mar 16 | 11,070 | 2,408 | 2,677 | 0 |
| 31 Dec 15 | 10,235 | 2,103 | 2,798 | 66 |
| 30 Sep 15 | 9,713 | 1,964 | 2,709 | 66 |
| 30 Jun 15 | 9,017 | 1,843 | 2,273 | 0 |
| 31 Mar 15 | 8,599 | 1,750 | 2,186 | 0 |
| 31 Mar 14 | 6,995 | 1,339 | 1,994 | 0 |
Quality Earnings: 539268 has high quality earnings.
Growing Profit Margin: 539268's current net profit margins (14%) are lower than last year (14.2%).
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: 539268's earnings have grown by 6.2% per year over the past 5 years.
Accelerating Growth: 539268's has had negative earnings growth over the past year, so it can't be compared to its 5-year average.
Earnings vs Industry: 539268 had negative earnings growth (-3.3%) over the past year, making it difficult to compare to the Life Sciences industry average (37.9%).
Return on Equity
High ROE: 539268's Return on Equity (11%) is considered low.